Marta Podda
YOU?
Author Swipe
View article: Advancing Neuroblastoma Surgery Through the Clinical Integration of Virtual Reality (VR) and Indocyanine Green (ICG) Fluorescence-Guided Imaging: A Case Report.
Advancing Neuroblastoma Surgery Through the Clinical Integration of Virtual Reality (VR) and Indocyanine Green (ICG) Fluorescence-Guided Imaging: A Case Report. Open
Background: Neuroblastoma, the most common extracranial solid tumor in children, requires meticulous surgical interventions due to its complex anatomical location and proximity to vital structures. Emerging technologies, such as Virtual re…
View article: Pediatric Craniofacial Osteosarcoma: The Milano Experience
Pediatric Craniofacial Osteosarcoma: The Milano Experience Open
Background Craniofacial osteosarcoma (CFOS) is a rare tumor, typically affecting patients over 60, with a low incidence of metastasis at diagnosis as well as at relapse. Patients and methods This study analyzed patients treated for high‐gr…
View article: Malignant Peripheral Nerve Sheath Tumor in Children and Adolescents: Local Treatment in a Retrospective Single‐Center Experience
Malignant Peripheral Nerve Sheath Tumor in Children and Adolescents: Local Treatment in a Retrospective Single‐Center Experience Open
Background Malignant peripheral nerve sheath tumor (MPNST) is a rare and aggressive sarcoma often associated with neurofibromatosis type 1, whose clinical management remains complex and challenging. Few publications exist on pediatric MPNS…
View article: Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW‐1): A Randomized, Open‐Label, Phase 3, Non‐Inferiority Trial
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW‐1): A Randomized, Open‐Label, Phase 3, Non‐Inferiority Trial Open
Background Several studies have shown that the intensity of treatment in Ewing sarcoma has an impact on outcome. The present trial tested the non‐inferiority of intensive, shorter, induction chemotherapy (25 weeks total treatment time) com…
View article: Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype Open
Background We applied the strategy for M+ medulloblastoma across all high-risk subgroups, including LC/A histology, TP53 mutations, and MYC/MYCN amplification. Methods Patients over 3 years old received, after surgery, staging and histo-bi…
View article: Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan
Foreign patients and multicultural challenges in pediatric oncology: The experience of the Istituto Nazionale dei Tumori in Milan Open
This paper describes the complexity of the clinical management of foreign minors suffering from cancer, through the clinical experience of an Italian referral center. The study includes 50 patients less than 18 years (22% of the patients a…
View article: ATRT-06. PEDIATRIC INI1-NEGATIVE ATYPICAL TERATOID RHABDOID TUMORS TREATED WITH TAZEMETOSTAT AS MAINTENANCE THERAPY IN THE RELAPSE SETTING: AN ITALIAN SINGLE-CENTRE EXPERIENCE
ATRT-06. PEDIATRIC INI1-NEGATIVE ATYPICAL TERATOID RHABDOID TUMORS TREATED WITH TAZEMETOSTAT AS MAINTENANCE THERAPY IN THE RELAPSE SETTING: AN ITALIAN SINGLE-CENTRE EXPERIENCE Open
BACKGROUND Rhabdoid tumors are aggressive malignancies, primarily affecting children ≤3 years. Common sites of primary localization are kidney, central nervous system (atypical teratoid rhabdoid tumor -AT/RT-) or soft tissues. Although hig…
View article: DIPG-04. THE BENEFIT OF CRANIOSPINAL IRRADIATION (CSI) RESCUE IN PHASE 2 RANDOMIZED STUDY OF RADIOTHERAPY (RT), CONCOMITANT NIMOTUZUMAB AND VINORELBINE AND RE-IRRADIATION AT RELAPSE, VERSUS MULTIPLE ELECTIVE RADIOTHERAPY COURSES WITH CONCOMITANT VINORELBINE AND NIMOTUZUMAB FOR NEWLY DIAGNOSED CHILDHOOD AND ADOLESCENCE DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
DIPG-04. THE BENEFIT OF CRANIOSPINAL IRRADIATION (CSI) RESCUE IN PHASE 2 RANDOMIZED STUDY OF RADIOTHERAPY (RT), CONCOMITANT NIMOTUZUMAB AND VINORELBINE AND RE-IRRADIATION AT RELAPSE, VERSUS MULTIPLE ELECTIVE RADIOTHERAPY COURSES WITH CONCOMITANT VINORELBINE AND NIMOTUZUMAB FOR NEWLY DIAGNOSED CHILDHOOD AND ADOLESCENCE DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) Open
BACKGROUND This trial evaluated feasibility,response,PFS/OS of a randomization comparing two different RT schedules for DIPG while administering the same systemic treatment. We moreover evaluated the benefit of craniospinal irradiation(CSI…
View article: MDB-04. LONG-TERM OUTCOME OF THE MILANO STRATEGY FOR HIGH-RISK MEDULLOBLASTOMA, INCLUDING THE IMPACT OF MOLECULAR SUBTYPE
MDB-04. LONG-TERM OUTCOME OF THE MILANO STRATEGY FOR HIGH-RISK MEDULLOBLASTOMA, INCLUDING THE IMPACT OF MOLECULAR SUBTYPE Open
BACKGROUND Since 2008 we have been using the same strategy as for M+ medulloblastoma for all other high-risk subgroups(LC/A histology,TP53 mutations,and/or MYC/MYCN amplification). METHODS After surgery,patients >3-year-old received stagin…
View article: GCT-18. GERMINOMAS OF THE CENTRAL NERVOUS SYSTEM (CNS): 20 YEARS EXPERIENCE WITH WHOLE VENTRICULAR IRRADIATION (WVI) AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILAN
GCT-18. GERMINOMAS OF THE CENTRAL NERVOUS SYSTEM (CNS): 20 YEARS EXPERIENCE WITH WHOLE VENTRICULAR IRRADIATION (WVI) AT FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILAN Open
BACKGROUND Intracranial germ cell tumors account for 1-3% of pediatric CNS tumors, with germinomas constituting up to 65%, their prognosis being favourable compared to the non-germinomatous counterpart. METHODS After an unsuccessful experi…
View article: Caring for children with cancer evacuated from Ukraine: The patients’ perception
Caring for children with cancer evacuated from Ukraine: The patients’ perception Open
Background and aims Since the beginning of the war in Ukraine on February 24, 2022, many pediatric oncology centers welcomed evacuated patients. To better understanding the needs of patients and families arriving at two Lombardy hospitals …
View article: Caring for children with cancer evacuated from Ukraine: the patients’ perception
Caring for children with cancer evacuated from Ukraine: the patients’ perception Open
Background and Aims. Since the war in Ukraine which began on February 2022, many pediatric oncology centers have welcomed patients from Ukraine. To understand the needs of patients and families arriving at our hospital, an anonymous questi…
View article: A HOMOGENEOUS TREATMENT FOR NON-DIPG DIFFUSE MIDLINE GLIOMA
A HOMOGENEOUS TREATMENT FOR NON-DIPG DIFFUSE MIDLINE GLIOMA Open
Introduction. The H3K27M-mutant diffuse midline glioma (DMG) was first included in the WHO Classification of CNS (central nervous system) tumors in 2016, and confirmed in its fifth edition. The biological behavior and dismal prognosis of t…
View article: Local treatment in initially unresected non‐rhabdomyosarcoma soft‐tissue sarcomas of children and adolescents: A retrospective single‐center experience
Local treatment in initially unresected non‐rhabdomyosarcoma soft‐tissue sarcomas of children and adolescents: A retrospective single‐center experience Open
Background Pediatric non‐rhabdomyosarcoma soft‐tissue sarcomas (NRSTS) are a heterogeneous group of aggressive tumors. Patients with locally advanced/initially unresected disease represent a subset of patients with unsatisfactory outcome: …
View article: PROLONGED COVID-19 INFECTION IN A CHILD WITH LYMPHOBLASTIC NON HODGKIN LYMPHOMA: WHICH IS THE BEST MANAGEMENT?
PROLONGED COVID-19 INFECTION IN A CHILD WITH LYMPHOBLASTIC NON HODGKIN LYMPHOMA: WHICH IS THE BEST MANAGEMENT? Open
During SARS-CoV-2 pandemic, oncologists manage patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments comp…
View article: Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients Open
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase predominantly expressed in the developing nervous system. Recently, mutated ALK has been identified as a major oncogene associated with familial and sporadic neuroblastomas (NB…
View article: Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients Open
Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
View article: Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients Open
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase predominantly expressed in the developing nervous system. Recently, mutated ALK has been identified as a major oncogene associated with familial and sporadic neuroblastomas (NB…
View article: Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients Open
Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
View article: Treating secondary malignant neoplasms: A burden of childhood cancer survivors
Treating secondary malignant neoplasms: A burden of childhood cancer survivors Open
Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combination of chemotherapy, radiotherapy, and su…
Neuroblastic tumors and neurofibromatosis type 1: A retrospective multicenter study in Italy and systematic review of the literature Open
Background Neuroblastic tumors (NBTs) are the most common extra-cranial solid tumors of childhood. Neurofibromatosis type 1 (NF1) is the most common neurocutaneous disorder with a predisposition to tumors. The co-occurrence of NBTs in the …
View article: Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables
Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables Open
Background Patients with relapsing rhabdomyosarcoma (RMS) pose a therapeutic challenge, and the survival rate is reportedly poor. We describe a retrospective series of relapsing RMS patients treated at a referral center for pediatric sarco…
View article: Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin’s Lymphoma in Children
Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin’s Lymphoma in Children Open
Early-stage non-Hodgkin’s lymphomas (ES-NHL) are associated with high survival rates. To minimize the risk of long-term sequelae, the duration and intensity of chemotherapy have been progressively reduced. Between 1988 and 2018, children w…
View article: A homogeneous treatment for non-DIPG diffuse midline glioma
A homogeneous treatment for non-DIPG diffuse midline glioma Open
Introduction: The H3K27M-mutant diffuse midline glioma (DMG) was first included in the World Health Organization (WHO) Classification of central nervous system (CNS) tumors in 2016, and confirmed in its fifth edition. The biological behavi…
View article: How ten-years of reirradiation for paediatric high-grade glioma can shed light on first line treatment
How ten-years of reirradiation for paediatric high-grade glioma can shed light on first line treatment Open
Purpose . Recurrence incidence for paediatric/adolescent high-grade glioma(HGG) exceeds 80%. Reirradiation(reRT) palliates symptoms and delays further progression. Strategies for reRT are scarce: we retrospectively analysed our series to d…
View article: SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life Open
INTRODUCTION: For terminally-ill children with brain tumors care focuses on quality of life, and patient management fundamentally affects grieving families. We describe our experience of palliative sedation (PS) for children with refractor…
View article: DIPG-04. Feasibility and early results of phase 2 open label randomized study of radiotherapy(RT), concomitant nimotuzumab and vinorelbine and re-irradiation at relapse, versus multiple elective radiotherapy courses with concomitant vinorelbine and nimotuzumab for newly diagnosed childhood and adolescence Diffuse intrinsic Pontine Glioma (DIPG)
DIPG-04. Feasibility and early results of phase 2 open label randomized study of radiotherapy(RT), concomitant nimotuzumab and vinorelbine and re-irradiation at relapse, versus multiple elective radiotherapy courses with concomitant vinorelbine and nimotuzumab for newly diagnosed childhood and adolescence Diffuse intrinsic Pontine Glioma (DIPG) Open
BACKGROUND: The purposes of this trial were to evaluate the feasibility, response, PFS/OS of a randomized study comparing two different RT schedules for DIPG while administering the same systemic treatment. METHODS: Patients: 2-21 years-ol…
View article: Managing Care during the COVID-19 Pandemic: The Point of View and Fears of Pediatric Cancer Patients’ Families
Managing Care during the COVID-19 Pandemic: The Point of View and Fears of Pediatric Cancer Patients’ Families Open
(1) Background: When the COVID-19 pandemic arrived, changes had to be made to several management aspects at our Pediatric Oncology Unit. We investigated how the families perceived these changes. (2) Methods: Two questionnaires were develop…